HK Stock Market Move | LEPU BIO-B(02157) closed up more than 14%, MRG003 is about to be listed and is expected to become the first domestic EGFR ADC.

LEPU BIO-B (02157) rose more than 14% in the afternoon session, up 8.83% at the time of publication, at 4.56 Hong Kong dollars, with a turnover of 2.37 billion Hong Kong dollars. In terms of news, Lepu Biology previously announced that the key phase IIb study results of the company's independently developed candidate drug MRG003 have been selected as a heavyweight research abstract (LBA) for the 2025 annual meeting of the American Society of Clinical Oncology, where an oral presentation will be made. MRG003 is a monoclonal antibody drug conjugate targeting the epidermal growth factor receptor, mainly used for the treatment of recurrent or metastatic nasopharyngeal carcinoma. Pacific Securities pointed out that MRG003 is Lepu Biology's EGFR-targeted ADC, and the nasopharyngeal carcinoma NDA has been officially accepted by the CDE and included in the priority review, with the possibility of being approved by the end of 2025 or early 2026, becoming the first domestically commercialized EGFR ADC. MRG003 is also undergoing clinical trials in the United States and has been granted BTD by the FDA. Huachun Securities also stated that Lepu Biology has multiple products in the late stages of research and development, with upcoming listings, a rich ADC pipeline, and a positive outlook on the company's differentiated indications layout for ADC monotherapy/combo therapy.